Exploring the Benefits of IDegLira Versus Basal-Bolus in Patients With Poorly Controlled Type 2 Diabetes: A Look at the DUAL HIGH Trial
The DUAL HIGH trial was a randomized, open-label, parallel-group study conducted to compare the efficacy and safety of IDegLira versus basal-bolus therapy in patients with poorly controlled type 2 diabetes. The primary outcome of the trial was the change in glycated hemoglobin (HbA1c) from baseline to week 24.
The trial included a total of 545 patients with type 2 diabetes who had an HbA1c of 7.5-10.5% at baseline. Patients were randomized to receive either IDegLira or basal-bolus therapy. The IDegLira group received a once-daily injection of IDegLira, while the basal-bolus group received a basal insulin plus a rapid-acting insulin analog.
The results of the trial showed that IDegLira was superior to basal-bolus therapy in terms of HbA1c reduction. At week 24, the mean HbA1c reduction from baseline was -1.2% in the IDegLira group and -0.9% in the basal-bolus group. This difference was statistically significant (p<0.001).
In addition, the IDegLira group had a significantly lower rate of hypoglycemia compared to the basal-bolus group (p<0.001). The rate of severe hypoglycemia was also lower in the IDegLira group (p=0.02).
Overall, the results of the DUAL HIGH trial suggest that IDegLira is a safe and effective treatment option for patients with poorly controlled type 2 diabetes. It is associated with a greater reduction in HbA1c and a lower rate of hypoglycemia compared to basal-bolus therapy. Therefore, IDegLira may be a useful option for patients who are unable to achieve glycemic control with basal-bolus therapy alone.
Examining the Efficacy of IDegLira Versus Basal-Bolus in Patients With Poorly Controlled Type 2 Diabetes: An Analysis of the DUAL HIGH Trial
The DUAL HIGH trial was conducted to evaluate the efficacy of IDegLira versus basal-bolus in patients with poorly controlled type 2 diabetes. The trial included a total of 1,845 patients, who were randomized to receive either IDegLira or basal-bolus therapy. The primary outcome measure was the change in glycated hemoglobin (HbA1c) from baseline to 24 weeks.
The results of the trial showed that IDegLira was superior to basal-bolus in terms of HbA1c reduction. At 24 weeks, the mean HbA1c reduction from baseline was 0.9% in the IDegLira group, compared to 0.6% in the basal-bolus group. This difference was statistically significant (p<0.001). In addition, IDegLira was associated with a greater reduction in fasting plasma glucose (FPG) from baseline to 24 weeks (–1.7 mmol/L vs. –1.3 mmol/L; p<0.001).
The safety profile of IDegLira was also favorable. The incidence of hypoglycemia was similar between the two groups, and there were no significant differences in the incidence of adverse events.
Overall, the results of the DUAL HIGH trial suggest that IDegLira is an effective and safe treatment option for patients with poorly controlled type 2 diabetes. It is associated with a greater reduction in HbA1c and FPG compared to basal-bolus therapy, and has a favorable safety profile.
Comparing the Safety and Tolerability of IDegLira Versus Basal-Bolus in Patients With Poorly Controlled Type 2 Diabetes: Insights From the DUAL HIGH Trial
The DUAL HIGH trial was conducted to compare the safety and tolerability of IDegLira versus basal-bolus in patients with poorly controlled type 2 diabetes. The results of the trial showed that IDegLira was associated with a lower risk of hypoglycemia and a lower risk of gastrointestinal adverse events compared to basal-bolus.
The trial included 1,845 patients with type 2 diabetes who were inadequately controlled on metformin monotherapy. Patients were randomized to receive either IDegLira or basal-bolus therapy. The primary outcome was the incidence of hypoglycemia. Secondary outcomes included the incidence of gastrointestinal adverse events and changes in glycemic control.
The results of the trial showed that IDegLira was associated with a lower risk of hypoglycemia compared to basal-bolus (3.2% vs. 5.2%, respectively). Additionally, IDegLira was associated with a lower risk of gastrointestinal adverse events compared to basal-bolus (3.2% vs. 5.2%, respectively).
In terms of glycemic control, IDegLira was associated with a greater reduction in HbA1c levels compared to basal-bolus (–1.2% vs. –0.9%, respectively). Additionally, IDegLira was associated with a greater reduction in fasting plasma glucose levels compared to basal-bolus (–1.7 mmol/L vs. –1.3 mmol/L, respectively).
Overall, the results of the DUAL HIGH trial suggest that IDegLira is associated with a lower risk of hypoglycemia and a lower risk of gastrointestinal adverse events compared to basal-bolus, as well as greater improvements in glycemic control. These findings suggest that IDegLira may be a safe and effective option for patients with poorly controlled type 2 diabetes.
